Table 2.
FDA approved Antibody-Drug Conjugates and selected others undergoing clinical development for cancer therapy
| Generic name | Trade/code name | Target | Antibody source | Antibody isotype | Other manipulations | Conjugated to: | Clinical status | Indication |
|---|---|---|---|---|---|---|---|---|
| Gemtuzumab ozogamicin |
Mylotag® |
CD33 |
Mouse monoclonal |
IgG4- kappa |
Humanized |
Calicheamicin |
Approved 2000 WITHDRAWN 2010 |
CD33+AML |
| Brentuximab vedotin |
Adcentris™ |
CD30 (TNFR) |
Mouse monoclonal |
IgG1- kappa |
Chimeric |
Monomethyl auristatin E (MMAE) |
Approved 2011 |
HL |
| Trastuzumab emtansine |
MCC-DM1/ T-DM1 |
HER-2 |
Mouse monoclonal |
IgG1- kappa |
Humanized |
Maytansinoid DM1 |
Phase III |
HER-2+ MBC |
| Inotuzumab ozogamicin |
CMC-544 |
CD22 |
Mouse monoclonal |
IgG4- kappa |
Humanized |
Calicheamicin |
Phase III Phase II |
NHL DLBCL |
| Lorvotuzumab mertansine |
IMGN901 |
CD56 |
Mouse monoclonal |
IgG1- kappa |
Humanized |
Maytansinoid DM1 |
Orphan Drug 2010; Phase II |
SMLC, OC, MM |
| ------ | SAR3419 | CD19 | Mouse monoclonal | IgG1 | Humanized | Maytasinoid DM4 | Phase I | NHL |
Legend: AML – Acute myologenous leukemia; HL – Hodgkin’s lymphoma; NHL – Non Hodglin’s Lymphoma, MM – Multiple Myeloma; DLBLC – Diffuse large B cell lymphoma; OC – Ovarian cancer; MBC – Metastatic breast cancer.